Case Studies: Use of Salicylic Acid (Avosil) and Hydrogel (Avogel) in Limiting Scar Formation by Danielson, John R. & Walter, Robert J.
Case Studies: Use of Salicylic Acid (Avosil) and
Hydrogel (Avogel) in Limiting Scar Formation




Objective: The purpose of this report is to present the results of a preliminary treatment
regimen for hypertrophic scars combining topical 2% salicylic acid cream (Avosil) with
an overlay of hydrogel dressing (Avogel). Methods: The study group consisted of 3
patients with symptomatic hypertrophic scars: 2 presternal and 1 on the inner thigh.
Scars were divided into 3 equal-size areas: (1) untreated control, (2) hydrogel alone,
and (3) 2% salicylic acid with hydrogel cover. Treatments were applied every 8 to 12
hours and a Velcro appliance was employed to cover the area during treatment. The total
length of treatment was 60 days. Results: At the end of the 60-day treatment protocol,
the area treated with 2% salicylic acid and hydrogel was asymptomatic. In contrast, the
hydrogel-treated and untreated control areas remained erythematous and symptomatic
for burning pain and pruritis. Conclusion: This small study suggests the efficacy of
combined salicylic acid and hydrogel therapy in the treatment of hypertrophic scars.
More extensive studies of scar treatment with salicylic acid and hydrogel are needed.
These studies must be larger in scope to carefully document the spectrum of patient
responses and should include methods for evaluating alterations in the levels of different
inflammatory mediators.
Thirty years ago, Larson et al observed that elastic pressure wrap dressings were
effective in reducing scar hypertrophy in healing burn scars.1 Since that report, 20 to 24
mm Hg pressure garments have become the mainstay of scar prevention. The mechanism
of action of pressure dressings is uncertain, particularly in view of the fact that they remain
effective following several weeks of daily use despite a loss of elasticity and a diminution
of pressure exertion. Biochemical assays of tissue healing beneath pressure garments show
moderate decreases in wound metabolism and increased collagenase activity.2 However,
pressure garments are poorly tolerated because of the general discomfort and restriction of
movement that accompanies their use.
In the past decade, another topical device, silicone gel sheeting, has been found to be
useful clinically in controlling scar formation.3−5 As with elastic garments, the mechanism
ofactionhasnotbeenconvincinglyelucidatedbutpostulatedmechanismsincludeinduction
of scar hypoxia, increased hydration of the epidermis covering the scar,6 and increased scar
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temperature.7,8 The effect does not depend on the composition of the gel sheeting used,
and it is clear that release of silicone into the scar is not the mode of action. Recently,
several reports have shown that hydrogel sheeting is just as effective as silicone but has
fewer adverse side effects.9,10 Hydrogel sheeting has been approved by the Food and Drug
Administration and is considered to be substantially equivalent to silicone for treatment
of hypertrophic scars. Thus, the effect of the topical gel sheeting seems independent of
its composition. Hydrogels have the added advantages of being useful as drug-delivery
vehicles and of having higher heat capacities for buffering scar temperature.8
Inflammationiscriticallyimportantforhealingandscarring.Dangetal11andO’Kane12
recently reviewed the biology of scar formation. Both reviews underscore the importance
of inflammation as the essential epigenetic stimulator of scarring. Therefore, we performed
a pilot investigation of topical salicylic acid (2%) treatment in conjunction with hydrogel
sheeting to determine whether there is an added beneficial effect from using a topical
nonsteroidal anti-inflammatory drug in scar management. Here, we report our experience
with the first patients.
METHODS
The first 2 cases were part of an ongoing pilot study at St. Mary’s Hospital designed to
document the effect of topically applied salicylic acid on symptomatic hypertrophic scars.
Both patients had tender and pruritic hypertrophic scars following median sternotomy. For
study inclusion, the length of the scar needed to be sufficient to accommodate a control
area and 2 experimental areas (each of equal size). The control area was left untreated
while one experimental area was covered with Avogel hydrogel (Avocet Polymer Tech-
nologies, Inc, Chicago, Ill) and a second area of equal length was treated with 2% sali-
cylic acid in Eucerin (Beiersdor, Wilton, Conn) and covered with Avogel hydrogel. The
study regimen called for treatments to be performed for 8 to 12 hours per day employ-
ing a Velcro appliance specially constructed to cover the scar during treatment and to
prevent salicylic acid from spreading into the control areas. Exclusion criteria included
the use of anti-inflammatory agents during the previous 2 weeks or known allergies to




The third patient was treated in a similar fashion by a Chicago area plastic surgeon
for an 11-month-old hypertrophic scar from a burn injury on the inner thigh. This case is
includedtodemonstratethatsimilareffectshavebeenobservedindependently.Theprotocol
used to treat this patient is described below.
Ethics
The Institutional Review Board of St. Mary’s Hospital approved this study, and all partici-
pants gave informed consent. The procedures followed were in accordance with the ethical
standardsassetforthbytheinstitutionandwiththeHelsinkiDeclarationof1975,asrevised
in 1983.
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RESULTS
All patients experienced significant symptomatic relief from tenderness and pain within
days in the area of the scar treated with 2% salicylic acid and hydrogel. Some relief in
symptoms was recorded in the area treated with hydrogel alone, but no symptomatic relief
wase xperienced in the untreated area. Noticeable decreases in scar width and height were
noted in all patients over the 60-day study period in the area treated with salicylic acid and
hydrogel. Comparatively small changes in scar dimensions were noted with hydrogel alone,
and no change was noted in the control region. Toward the end of the study period, scar




This patient is a 49-year-old man (Fig 1) who underwent open-heart surgery 6 months prior
to presentation at our clinic. The patient’s scar was 22 cm long, varied from 5 to 8 mm in
width, and was elevated by 2 to 3 mm throughout. He complained of tenderness to touch
and pain. After starting on the treatment protocol, all symptoms abated in the area treated
with 2% salicylic acid and hydrogel within 2 weeks. During subsequent weeks, the scar
height of the experimentally treated area decreased dramatically such that the scar became
completelyflattenedtotheleveloftheadjacenttissue.Thecontrolarearemainedunchanged,
andtheexperimentalareatreatedwithhydrogelalonedidnotresolveasmarkedlyasthearea
treated with 2% salicylic acid and hydrogel together. Furthermore, the degree of erythema
decreased in the area treated with 2% salicylic acid and hydrogel, whereas the scar color
remained unchanged in the area treated with hydrogel alone. At the end of the 60-day
treatment protocol, the area treated with 2% salicylic acid and hydrogel was asymptomatic.
In contrast, the hydrogel-treated and untreated control areas remained erythematous and
symptomatic for burning pain and pruritis.
Case #2
This patient is a 65-year-old woman (Fig 2) who underwent open-heart surgery 21/ 2 years
prior to presentation at our clinic. Before the study, she had applied vitamin E topically to
the scar for a short period of time without effect. She complained of pain and tenderness,
and the scar was very elevated and erythematous. The patient’s scar was 14 cm long, varied
from 4 to 6 mm in width, and was elevated by 3 to 4 mm. Symptomatic relief from pruritis
and tenderness occurred within 48 hours of applying salicylic acid and hydrogel. One week
afterbeginningthestudyregimen,shenotedamarkeddecreaseinsymptomsanddecreased
erythemainthisarea.Regressioninthesizeofthescarwaslessimpressive,butsymptomatic
relief was significant. After 60 days of treatment, her symptoms in the area treated with
2% salicylic acid and hydrogel had completely abated. The hydrogel-treated and untreated
control areas remained symptomatic.
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Figure 1. This patient is a 49-year-old man who underwent open-heart surgery 6 months prior to
presentation at our clinic. At the end of the 60-day treatment protocol, the area treated with 2%
salicylicacidandhydrogelwasasymptomaticandshowedreducederythema,whereasthehydrogel-
treated and untreated control areas remained erythematous and symptomatic for burning pain and
pruritis.
Case #3
This patient is a 42-year-old firefighter who suffered a flame burn injury to the skin on the
left inner thigh 11 months before presentation. He was treated as an outpatient at one of the
burn centers in Chicago where he received topical anti-microbials and dressing changes.
Thewoundhealedbyepithelializationandhypertrophicscarring.Thepatientwasreferredto
the University of Chicago Scar Clinic because the burn scar had become quite hypertrophic
and was unresponsive to compression stocking therapy. A photograph of the scar taken at
that time is shown in Figure 3 (left). Using a visual analog scale of scar pruritus, the patient
scored itch intensity at 6/10 (where 10 = unbearable itching) and itch frequency at 6/10
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Figure 2. This patient is a 65-year-old woman who underwent open-heart surgery 21/ 2 years
prior to presentation at our clinic. After 60 days of treatment, her symptoms in the area treated
with2%salicylicacidandhydrogelhadcompletelyabated.Thehydrogel-treatedanduntreated
control areas remained symptomatic.
(where 10 = itching at all times). With time, the scar continued to progressively increase
in thickness.
Therapy was initiated with Avogel hydrogel with 3% salicylic acid in a cream base
applied to the scar each night and left for 8 to 10 hours. The use of compression garment
therapy was discontinued. One month later, treatment regimen was adjusted such that 2%
acetylsalicylic acid in Eucerin ointment (Beiersdor, Wilton, Conn) with hydrogel was used
toachievebettersymptomaticrelief.On7-weekfollow-up(Fig3,right),thepatientshowed
a decrease in scar redness and thickness and a 50% reduction in the intensity of pruritus.
Scarsymptomswereexacerbatedbyworkactivity,inwhichheavyclothingabradedthescar,
but on 16-week follow-up, the scar manifested considerable involution and the intensity of
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Figure 3. This patient is a 42-year-old man seen 11 months after receiving a burn on the thigh.
Ah ypertrophic scar was evident (left panel) and the patient reported intense pruritis. In addition,
the scar was very elevated and erythematous. On 7-week follow-up after treatment with salicylic
acid and hydrogel (right panel), the scar showed a notable decrease in redness and thickness and
the patient reported diminished pruritus.
itching was scored as 3/10. The patient continues to be treated with salicylic acid (left
overnight for 8 hours).
DISCUSSION
Limitinginflammationisparamountinthecontrolofscargrowthandscar-associatedsymp-
toms. The inflammatory response can be regulated at several different physiological lev-
els. Three common ways that inflammation can be controlled are by inhibiting cytokine
production via cyclooxygenase (COX) regulation, inhibiting histamine binding to its recep-
tors, and inhibiting the NF-κB signal that upregulates inflammation. The most widely used
anti-inflammatory agents belong to the broad category of nonsteroidal anti-inflammatory
drugs. They inhibit either prostaglandin production or NF-κB generation or both. It is
noteworthy that steroids also exhibit anti-inflammatory effects by inhibiting inflammatory
response gene promoters NF-κB, AP-1 (activator protein-1), and NF-AT (nuclear factor of
activated T lymphocytes).13
The most common mode of prostaglandin synthesis blockade is inhibition of cell
membrane–bound COX. There are 2 isoforms of COX expressed in human cells, COX-1
and COX-2.14 COX-1 is expressed constitutively throughout the body, especially in stom-
ach and kidneys. On the other hand, COX-2 is expressed constitutively in the brain and
kidneys.15 COX-2 is highly inducible at sites of inflammation, playing an important
role in fibrosis. Many adverse side effects of COX inhibition are minimized by use of
specific COX-2 inhibitors, making them agents of choice for prolonged usage. The ther-
apeutic value of these agents in many rheumatologic diseases is well established. How-
ever, their potential value in management of hypertrophic scarring has been a more
recent consideration.16 NF-κBi sarapid response transcription factor that is involved in
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stress responses and is central to the inflammatory reaction.17 NF-κBi si n v olved in the
upregulation of both cell membrane receptors to inflammatory peptides and the produc-
tion of cytokines, chemokines, and growth factors. NF-κB activation can be inhibited by
several different agents, including cyclosporine, tacrolimus, antioxidants, and salicylates
(including aspirin). Salicylic acid inhibits NF-κBe xpression by blocking the dissociation
of IκB (the inactivator of NF-κB) from NF-κBi nthe cytoplasm and thus decreases the
amount of inflammation that occurs.17 At concentrations of 2% to 5%, salicylates are com-
monly used to control skin inflammation and are routinely used in over-the-counter acne
remedies.
Antihistamines are commonly used only to control the symptoms of scar pruritus.
However, they have other important effects that may function to reduce scarring. Antihis-
tamines, particularly H1 blockers, inhibit the inflammatory response, resulting in reduced
scar formation and reduced discomfort. Patients scratch the inflamed scar less frequently,
which probably reduces scar growth rate. Finally, antihistamines are well known to inhibit
collagen synthesis.18 Benadryl and Atarax are the most commonly used antihistamines
for scar management. In the past few years, we have preferred the use of long-acting,
nondrowsy formulations such as loratadine (Claritin; Schering, Kenilworth, NJ) or fexofe-
nadine (Allegra; Aventis, Kansas City, Mo), which have the advantages of sustained action
andfewercentralnervoussystemsideeffects.Inrecentstudies,topicallyappliedaspirinhas
been found to decrease histamine-induced wheal and flare reactions.19 However, topically
applied salicylic compounds did not diminish serotonin-induced scratching behavior in
rats.20
From the above, it is clear that more extensive studies of scar treatment with salicylic
acid and hydrogel are needed. These studies must be larger in scope to carefully document
the spectrum of patient responses and should include methods for evaluating alterations in
the levels of different inflammatory mediators.
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